GSK3A and melanoma: At variance, GSK3A, but not GSK3B, has been identified as a therapeutic target in melanoma [15] suggesting that, similarly to what has been reported for normal cells, the two isoforms can play both distinct or redundant roles depending on the cancer cell type.